SB606

New Hampshire SB606 mandates Medicaid coverage for biomarker testing deemed medically necessary.

New Hampshire SB606 amends the state Medicaid plan to require coverage for biomarker testing when deemed medically necessary by the New Hampshire Medicaid program. Biomarker testing, defined as the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, must be covered if it provides clinical utility and is supported by medical and scientific evidence. The bill outlines specific criteria for coverage, including labeled indications for FDA-approved tests, indicated tests for FDA-approved drugs, and warnings on FDA-approved drug labels.